Aura Biosciences, Inc. Common Stock
$6.73
-$0.19 (-2.75%)
$6.59Day Range$7.01
Key Statistics
Market Cap
$717.64M
Shares Outstanding
103.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 29, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$6.92
Day High
$7.01
Day Low
$6.59
Volume
1.29M
VWAP
$6.81
Prev Close
$6.92
Transactions
--
Acc. Volume
--
About Aura Biosciences, Inc. Common Stock
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836113 employees80 GUEST STREET, BOSTON, MA, 02135(617)500-8864IPO Oct 29, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001501796
- Composite FIGI
- BBG00226DGM5
- Share Class FIGI
- BBG00226DGP2
- Ticker Root
- AURA
- SIC Code
- 2836
About Aura Biosciences, Inc. Common Stock (AURA) Stock
Aura Biosciences, Inc. Common Stock (AURA) closed the 2026-09-16 session at $6.73, down 2.75% versus the previous close (-0.19). The stock opened at $6.92 and traded between $6.59 and $7.01 during that session. Session trading volume was 1.3M shares. The volume-weighted average price (VWAP) is $6.81.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Aura Biosciences, Inc. Common Stock has a market capitalization of $717.6 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. AURA is listed on the XNAS exchange. The company employs approximately 113 people. Aura Biosciences, Inc. Common Stock is headquartered in BOSTON, MA. The recorded listing date is 2021-10-29.
On this page you can find market AURA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.